Morgan Stanley Increases Elevance Health (NYSE:ELV) Price Target to $404.00

Posted by George Bondi on Jun 4th, 2026

Elevance Health (NYSE:ELV – Get Free Report) had its price target boosted by equities research analysts at Morgan Stanley from $352.00 to $404.00 in a report issued on Thursday,MarketScreener reports. Morgan Stanley’s target price points to a potential downside of 0.23% from the company’s previous close.

Several other research firms have also recently commented on ELV. UBS Group increased their target price on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research note on Friday, May 22nd. Barclays increased their price objective on shares of Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Evercore reissued a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Finally, Mizuho increased their price target on shares of Elevance Health from $385.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 20th. Fourteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $409.79.

Check Out Our Latest Analysis on Elevance Health

Elevance Health Stock Up 3.5%

Shares of NYSE ELV opened at $404.94 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health has a 1 year low of $273.71 and a 1 year high of $408.00. The stock’s 50-day simple moving average is $349.95 and its 200-day simple moving average is $340.65. The firm has a market cap of $87.94 billion, a price-to-earnings ratio of 17.22, a PEG ratio of 2.20 and a beta of 0.67.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. During the same quarter last year, the firm earned $11.97 EPS. Elevance Health’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts anticipate that Elevance Health will post 26.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. DV Trading LLC grew its position in shares of Elevance Health by 244.3% during the 1st quarter. DV Trading LLC now owns 964 shares of the company’s stock valued at $282,000 after buying an additional 684 shares during the last quarter. NewEdge Advisors LLC raised its stake in Elevance Health by 21.4% during the first quarter. NewEdge Advisors LLC now owns 18,964 shares of the company’s stock worth $5,552,000 after acquiring an additional 3,343 shares during the period. Axiom Investment Management LLC bought a new position in Elevance Health in the first quarter worth about $542,000. Groupama Asset Managment grew its holdings in shares of Elevance Health by 4.0% during the first quarter. Groupama Asset Managment now owns 8,757 shares of the company’s stock valued at $2,564,000 after purchasing an additional 333 shares during the last quarter. Finally, Wellington Grp LLC raised its position in shares of Elevance Health by 162.7% during the 1st quarter. Wellington Grp LLC now owns 704 shares of the company’s stock worth $206,000 after purchasing an additional 436 shares during the period. 89.24% of the stock is currently owned by institutional investors.

About Elevance Health

(Get Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.